Literature DB >> 989476

Bioavailability of tolamolol.

J K Faulkner, D A Stopher, R Walden, W Singleton, S H Taylor.   

Abstract

Bioavailability of capsule and tablet formulations of tolamolol were compared by measuring plasma concentration of tolamolol and reduction in maximum exercise heart rate over a period of twelve hours in eight healthy subjects in a two-way cross-over study. Tolamolol was absorbed more rapidly from capsules than from tablets; this did not result in any significant difference in the reduction in maximum exercise heart rate between the two formulations. There was no significant difference between area under curve of reduction in exercise tachycardia and area under-curve of plasma concentration of tolamolol for the two formulations. Reduction in maximum exercise heart rate was related to logarithm of plasma concentration of tolamolol between two and twelve hours after both formulations.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 989476     DOI: 10.1007/bf00561666

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  RESPONSIBILITY IN INVESTIGATIONS ON HUMAN SUBJECTS. STATEMENTS BY MEDICAL RESEARCH COUNCIL.

Authors:  P P RICKHAM
Journal:  Br Med J       Date:  1964-07-18

2.  Medical ethics.

Authors:  R Ormrod
Journal:  Br Med J       Date:  1968-04-06

3.  Thin layer chromatography-fluorimetic estimation of tolamolol in human plasma.

Authors:  D A Stopher
Journal:  J Pharm Pharmacol       Date:  1975-02       Impact factor: 3.765

4.  A comparative study of the activity of beta-adrenoceptor antagonists in man.

Authors:  S H Taylor; U Thadani; C Davidson; W singleton; S Myint
Journal:  Int J Clin Pharmacol Biopharm       Date:  1975-07

5.  Pharmacokinetic and pharmacological studies with tolamolol in man.

Authors:  J K Faulkner; D A Stopher; R Walden
Journal:  Br J Clin Pharmacol       Date:  1975-10       Impact factor: 4.335

6.  Beta-adrenoceptor blocking agents. 1. Cardioselective 1-aryloxy-3-(aryloxyalkylamino)propan-2-ols.

Authors:  J Augstein; D A Cox; A L Ham; P R Leeming; M Snarey
Journal:  J Med Chem       Date:  1973-11       Impact factor: 7.446

7.  The beta-blocking potency and cardioselectivity of tolamolol and its isomers in rodents.

Authors:  K R Adam; J R Baird; R A Burges; J Linnell
Journal:  Eur J Pharmacol       Date:  1974-02       Impact factor: 4.432

8.  Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man.

Authors:  D J Coltart; D G Shand
Journal:  Br Med J       Date:  1970-09-26

9.  Assessment of selective beta-adrenoceptor blockade in man.

Authors:  R H Briant; C T Dollery; T Fenyvesi; C F George
Journal:  Br J Pharmacol       Date:  1973-09       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.